Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Accumulated Expenses: 2022-2024

Historic Other Accumulated Expenses for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $289,000.

  • Corvus Pharmaceuticals' Other Accumulated Expenses rose 40.80% to $566,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $566,000, marking a year-over-year increase of 40.80%. This contributed to the annual value of $289,000 for FY2024, which is 17.96% up from last year.
  • Per Corvus Pharmaceuticals' latest filing, its Other Accumulated Expenses stood at $289,000 for FY2024, which was up 17.96% from $245,000 recorded in FY2023.
  • Corvus Pharmaceuticals' Other Accumulated Expenses' 5-year high stood at $289,000 during FY2024, with a 5-year trough of $158,000 in FY2022.
  • In the last 3 years, Corvus Pharmaceuticals' Other Accumulated Expenses had a median value of $245,000 in 2023 and averaged $230,667.
  • Data for Corvus Pharmaceuticals' Other Accumulated Expenses shows a peak YoY soared of 55.06% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Corvus Pharmaceuticals' Other Accumulated Expenses stood at $158,000 in 2022, then surged by 55.06% to $245,000 in 2023, then rose by 17.96% to $289,000 in 2024.